PubMed:30994353 / 697-842 JSONTXT

{"project":"GlyCosmos600-CLO","denotations":[{"id":"T2","span":{"begin":139,"end":144},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Furthermore, we confirmed that vemurafenib could compromise the ATP binding capacity of MAP2K5 in vitro and inhibit its kinase activity in cells."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T5","span":{"begin":0,"end":145},"obj":"Sentence"},{"id":"T5","span":{"begin":0,"end":145},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Furthermore, we confirmed that vemurafenib could compromise the ATP binding capacity of MAP2K5 in vitro and inhibit its kinase activity in cells."}

{"project":"GlyCosmos600-FMA","denotations":[{"id":"T3","span":{"begin":139,"end":144},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Furthermore, we confirmed that vemurafenib could compromise the ATP binding capacity of MAP2K5 in vitro and inhibit its kinase activity in cells."}

{"project":"pubmed-enju-pas","denotations":[{"id":"EnjuParser_T102","span":{"begin":0,"end":11},"obj":"RB"},{"id":"EnjuParser_T103","span":{"begin":11,"end":12},"obj":"-COMMA-"},{"id":"EnjuParser_T104","span":{"begin":13,"end":15},"obj":"PRP"},{"id":"EnjuParser_T105","span":{"begin":16,"end":25},"obj":"VBD"},{"id":"EnjuParser_T106","span":{"begin":26,"end":30},"obj":"IN"},{"id":"EnjuParser_T107","span":{"begin":31,"end":42},"obj":"NN"},{"id":"EnjuParser_T108","span":{"begin":43,"end":48},"obj":"MD"},{"id":"EnjuParser_T109","span":{"begin":49,"end":59},"obj":"VB"},{"id":"EnjuParser_T110","span":{"begin":60,"end":63},"obj":"DT"},{"id":"EnjuParser_T111","span":{"begin":64,"end":67},"obj":"NN"},{"id":"EnjuParser_T112","span":{"begin":68,"end":75},"obj":"NN"},{"id":"EnjuParser_T113","span":{"begin":76,"end":84},"obj":"NN"},{"id":"EnjuParser_T114","span":{"begin":85,"end":87},"obj":"IN"},{"id":"EnjuParser_T115","span":{"begin":88,"end":94},"obj":"NN"},{"id":"EnjuParser_T116","span":{"begin":95,"end":97},"obj":"FW"},{"id":"EnjuParser_T117","span":{"begin":98,"end":103},"obj":"FW"},{"id":"EnjuParser_T118","span":{"begin":104,"end":107},"obj":"CC"},{"id":"EnjuParser_T119","span":{"begin":108,"end":115},"obj":"VB"},{"id":"EnjuParser_T120","span":{"begin":116,"end":119},"obj":"PRP-DOLLAR-"},{"id":"EnjuParser_T121","span":{"begin":120,"end":126},"obj":"NN"},{"id":"EnjuParser_T122","span":{"begin":127,"end":135},"obj":"NN"},{"id":"EnjuParser_T123","span":{"begin":136,"end":138},"obj":"IN"},{"id":"EnjuParser_T124","span":{"begin":139,"end":144},"obj":"NNS"}],"relations":[{"id":"EnjuParser_R100","pred":"arg1Of","subj":"EnjuParser_T105","obj":"EnjuParser_T102"},{"id":"EnjuParser_R101","pred":"arg1Of","subj":"EnjuParser_T105","obj":"EnjuParser_T103"},{"id":"EnjuParser_R102","pred":"arg1Of","subj":"EnjuParser_T104","obj":"EnjuParser_T105"},{"id":"EnjuParser_R103","pred":"arg2Of","subj":"EnjuParser_T118","obj":"EnjuParser_T105"},{"id":"EnjuParser_R104","pred":"arg1Of","subj":"EnjuParser_T118","obj":"EnjuParser_T106"},{"id":"EnjuParser_R105","pred":"arg1Of","subj":"EnjuParser_T107","obj":"EnjuParser_T108"},{"id":"EnjuParser_R106","pred":"arg2Of","subj":"EnjuParser_T118","obj":"EnjuParser_T108"},{"id":"EnjuParser_R107","pred":"arg1Of","subj":"EnjuParser_T107","obj":"EnjuParser_T109"},{"id":"EnjuParser_R108","pred":"arg2Of","subj":"EnjuParser_T113","obj":"EnjuParser_T109"},{"id":"EnjuParser_R109","pred":"arg1Of","subj":"EnjuParser_T113","obj":"EnjuParser_T110"},{"id":"EnjuParser_R110","pred":"arg1Of","subj":"EnjuParser_T113","obj":"EnjuParser_T111"},{"id":"EnjuParser_R111","pred":"arg1Of","subj":"EnjuParser_T113","obj":"EnjuParser_T112"},{"id":"EnjuParser_R112","pred":"arg1Of","subj":"EnjuParser_T113","obj":"EnjuParser_T114"},{"id":"EnjuParser_R113","pred":"arg2Of","subj":"EnjuParser_T115","obj":"EnjuParser_T114"},{"id":"EnjuParser_R114","pred":"arg1Of","subj":"EnjuParser_T117","obj":"EnjuParser_T116"},{"id":"EnjuParser_R115","pred":"arg1Of","subj":"EnjuParser_T109","obj":"EnjuParser_T117"},{"id":"EnjuParser_R116","pred":"arg1Of","subj":"EnjuParser_T109","obj":"EnjuParser_T118"},{"id":"EnjuParser_R117","pred":"arg2Of","subj":"EnjuParser_T119","obj":"EnjuParser_T118"},{"id":"EnjuParser_R118","pred":"arg1Of","subj":"EnjuParser_T107","obj":"EnjuParser_T119"},{"id":"EnjuParser_R119","pred":"arg2Of","subj":"EnjuParser_T122","obj":"EnjuParser_T119"},{"id":"EnjuParser_R120","pred":"arg1Of","subj":"EnjuParser_T122","obj":"EnjuParser_T120"},{"id":"EnjuParser_R121","pred":"arg1Of","subj":"EnjuParser_T122","obj":"EnjuParser_T121"},{"id":"EnjuParser_R122","pred":"arg1Of","subj":"EnjuParser_T122","obj":"EnjuParser_T123"},{"id":"EnjuParser_R123","pred":"arg2Of","subj":"EnjuParser_T124","obj":"EnjuParser_T123"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":"Furthermore, we confirmed that vemurafenib could compromise the ATP binding capacity of MAP2K5 in vitro and inhibit its kinase activity in cells."}